Target Price | €178.00 |
Price | €118.95 |
Potential | 49.64% |
Number of Estimates | 16 |
16 Analysts have issued a price target Merck 2026 . The average Merck target price is €178.00. This is 49.64% higher than the current stock price. The highest price target is €206.00 73.18% , the lowest is €160.00 34.51% . | |
A rating was issued by 17 analysts: 15 Analysts recommend Merck to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 49.64% . Most analysts recommend the Merck stock at Purchase. |
15 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €22.0b . This is 4.11% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €22.4b 5.74% , the lowest is €21.2b 0.21% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €22.0b | 4.11% |
2026 | €23.0b | 4.24% |
2027 | €23.8b | 3.78% |
2028 | €25.2b | 5.71% |
2029 | €26.5b | 5.37% |
15 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.4b . This is 4.46% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.6b 0.84% , the lowest is €6.1b 8.41% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €6.2b | 5.89% |
---|---|---|
2025 | €6.4b | 3.16% |
2026 | €6.8b | 7.29% |
2027 | €7.1b | 4.72% |
2028 | €7.6b | 6.36% |
2029 | €8.2b | 7.67% |
2024 | 29.15% | 5.07% |
---|---|---|
2025 | 28.89% | 0.91% |
2026 | 29.73% | 2.91% |
2027 | 30.00% | 0.91% |
2028 | 30.19% | 0.63% |
2029 | 30.84% | 2.15% |
12 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.3b . This is 17.47% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.6b 28.55% , the lowest is €2.8b 0.94% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.69% |
---|---|---|
2025 | €3.3b | 17.47% |
2026 | €3.7b | 12.08% |
2027 | €3.9b | 7.85% |
2028 | €4.3b | 8.63% |
2029 | €4.7b | 8.98% |
2024 | 13.13% | 2.45% |
---|---|---|
2025 | 14.82% | 12.85% |
2026 | 15.93% | 7.49% |
2027 | 16.56% | 3.95% |
2028 | 17.01% | 2.72% |
2029 | 17.60% | 3.47% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €7.51 . This is 17.53% higher than earnings per share in the financial year 2024. The highest EPS forecast is €8.21 28.48% , the lowest is €6.45 0.94% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €7.51 | 17.53% |
2026 | €8.41 | 11.98% |
2027 | €9.07 | 7.85% |
2028 | €9.86 | 8.71% |
2029 | €10.74 | 8.92% |
Current | 18.40 | 22.17% |
---|---|---|
2025 | 15.66 | 14.89% |
2026 | 13.97 | 10.79% |
2027 | 12.96 | 7.23% |
2028 | 11.93 | 7.95% |
2029 | 10.94 | 8.30% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.68 and an P/S ratio of 2.32 .
This results in the following potential growth metrics and future valuations:
Current | 2.79 | 21.41% |
---|---|---|
2025 | 2.68 | 4.04% |
2026 | 2.57 | 4.07% |
2027 | 2.47 | 3.64% |
2028 | 2.34 | 5.41% |
2029 | 2.22 | 5.10% |
Current | 2.42 | 24.06% |
---|---|---|
2025 | 2.32 | 3.95% |
2026 | 2.23 | 4.07% |
2027 | 2.14 | 3.64% |
2028 | 2.03 | 5.40% |
2029 | 1.93 | 5.10% |
Analyst | Rating | Action | Date |
---|---|---|---|
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Apr 06 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 01 2025 |
DAY BY DAY |
Sell
➜
Sell
|
Unchanged | Mar 30 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Mar 16 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Mar 10 2025 |
JEFFERIES |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Apr 06 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 01 2025 |
Unchanged
DAY BY DAY:
Sell
➜
Sell
|
Mar 30 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Mar 16 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Mar 10 2025 |
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.